Breaking News

FDA reverses decades-old cancer warning on hormone therapy

November 11, 2025
James Watson in a 2004 photo taken at an exhibit in Berlin.
Markus Schreiber/AP

James Watson, dead at 97, was a scientific legend and a pariah among his peers

The complicated story of James Watson, whose landmark DNA discovery with Francis Crick was later overshadowed by his deeply offensive remarks

By Sharon Begley


STAT+ | Fate of ACA subsidies still clouded after deal to reopen the government

Democrats negotiated a future vote on Affordable Care Act tax credits in return for reopening the government, but there's no guarantee of passage.

By John Wilkerson


STAT+ | China's biotech boom is being driven by a dazzling market rebound

Investor optimism and state support are fueling growth in China's biotech industry as it seeks to surpass its peers in the U.S. in innovation.

By Liyan Qi



Hormone replacement patches are seen in 2003, the year the FDA put a black box warning on the therapies. The agency reversed its decision on Monday.
Ian Waldie/Getty Images

FDA reverses decades-old warning on hormone therapy products for menopause

FDA removes black box warning on hormone therapy, reflecting new science on menopause, heart health, and evolving views on women's care.

By Theresa Gaffney and Chelsea Cirruzzo


More around STAT

In case you missed it

  • Drugmakers pile into a cancer gold rush with questionable payoff, Bloomberg
  • Novartis opens new plant in California to make cancer drugs, Reuters
  • India launches first indigenous CAR-T cell therapy NexCAR19 for blood cancer treatment, Digital Health News

Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments